Spyre Therapeutics, Inc. SYRE Debt-to-equity
Discontinued — last reported Q1 '23
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 9, 2024, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s debt-to-equity?
- Spyre Therapeutics, Inc. (SYRE) reported debt-to-equity of 0.1× in Q1 2023.
- How has Spyre Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Spyre Therapeutics, Inc.'s debt-to-equity increased by 64.8% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Spyre Therapeutics, Inc.'s debt-to-equity?
- Over 2 years (2020 to 2022), Spyre Therapeutics, Inc.'s debt-to-equity has grown at a 52.9% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.